evidence: Compared to patients treated for 24 weeks, the SVR rate in those treated for 48 weeks increased by 10.9% [95% CI: −5.9% to 27.7%] and 65.6% [95% CI: 44.5% to 86.7%] if they had IL-28B rs8099917 TT genotype, and GT/GG genotype, respectively (interaction P = 0.002).
intervention: peginterferon (Peg-IFN) plus ribavirin (RBV) for 48 weeks
comparator: peginterferon (Peg-IFN) plus ribavirin (RBV) for 24 weeks
outcome: The SVR rates if the patients had IL-28B rs8099917 TT genotype, and GT/GG genotype